相关实验视频
Updated: Jan 9, 2026
05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.7K
在动脉样硬化中解码Kruppel类转录因子:从分子和转化角度的洞察力
Yiyang Cao1, Chenyue Wang1, Xuzhou Zhu1
1The Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
International journal of molecular sciences
|December 11, 2025
概括
克鲁佩尔样因子 (KLF) 是动脉样硬化发展的关键调节者. 用新物质,基因疗法或纳米技术准KLF途径为动脉样硬化心血管疾病提供了有前途的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 翻译医学是一种翻译医学.
背景情况:
- 动脉样硬化是心血管和脑血管疾病的主要原因,由炎症,脂质问题和血管重塑驱动.
- 目前的治疗方法,如改变生活方式和服用他类药物,都有局限性,死亡率和发病率仍然很高.
- 克鲁佩尔样因子 (KLF) 是影响许多生理和病理过程的关键转录因子.
研究的目的:
- 构建一个全面的网络,说明KLFs在动脉样硬化病原体中的作用.
- 确定针对KLF调节动脉样硬化途径的新型治疗物质和方法.
- 探索基因疗法和纳米技术用于动脉样硬化心血管疾病的精密医学.
主要方法:
- 文献综述侧重于KLFs在动脉样硬化中的分子机制.
- 建立网络,绘制动脉样硬化病变发展中的KLF相互作用.
- 分析新兴的治疗策略,包括基因疗法和纳米技术.
主要成果:
- 特定的KLF家族成员 (KLF2,KLF4,KLF5,KLF6,KLF14) 在调节内皮平衡,光滑肌细胞变化和炎症方面是至关重要的.
- 针对KLF通路的新物质显示出减轻动脉样硬化的潜力.
- 基因疗法和纳米技术为KLF调节治疗提供了新兴的方法.
结论:
- KLF在动脉样硬化病变的开始和进展中发挥着中心作用.
- 准KLF通路为动脉样硬化心血管疾病提供了新的治疗途径.
- 本综述强调了KLF调制的翻译和精确医学潜力.
相关概念视频
01:30Atherosclerosis I: Introduction
795
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
795
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
434
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
434
01:26Coronary Artery Disease II: Pathophysiology
340
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
340
01:38Inflammation
61.4K
Overview
61.4K
01:30Coronary Artery Disease I: Introduction
847
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
847